The FDA Antimicrobial Drugs Advisory Committee (AMDAC) will convene on 30 November 2021 to discuss Merck and Ridgeback’s request for emergency use (EUA) of molnupiravir oral capsules for treatment of mild to moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization. an investigational antiviral drug to treat COVID-19. FDA
Calendar of Events
M
Mon
|
T
Tue
|
W
Wed
|
T
Thu
|
F
Fri
|
S
Sat
|
S
Sun
|
---|---|---|---|---|---|---|
0 events,
|
2 events,
Virtual Event
-
Virtual Event
Virtual Event
-
Virtual Event
The COVID-19 pandemic has illuminated and exacerbated challenges in caring for people of all ages with serious illness. The response to many of these challenges involved rapid innovation and as such provides valuable lessons learned that will likely significantly alter the field of serious illness care in the post-pandemic era. The Roundtable on Quality Care |
0 events,
|
0 events,
|
1 event,
Virtual Event
A virtual science conference on One Health: Integrating Human, Animal and Environmental Health will be held 3 December 2021. The One Health movement, which has come to prominence in the last decade, advocates greater cross-sectoral collaboration and communication across the human-animal-environment interface. There has been a long-standing recognition that population health is intrinsically linked to |
0 events,
|
0 events,
|
0 events,
|
0 events,
|
1 event,
Virtual Event
-
Virtual Event
The NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) is partnering with the Swiss Centre for Applied Human Toxicology and the Swiss State Secretariat for Economic Affairs to present a webinar series on “Current Concepts in Quantitative Risk Assessment for Skin Sensitization.” The next webinar in the series on December 8 will |
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
1 event,
Virtual Event
The National Biodefense Science Board (NBSB) will meet in public (virtually) on December 16, 2021, to provide advice and recommendations to ASPR regarding the development of the 2023-2026 National Health Security Strategy and to discuss other matters of current important for public health emergency preparedness, response, and recovery. A more detailed agenda will be available |
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|